3933. Fampridine

Nomenclature

CAS number: 504-24-5
4-Pyridinamine; 4-aminopyridine; γ-aminopyridine; 4-pyridylamine; 4-AP; EL-970.
C5H6N2; mol wt 94.11.
C 63.81%, H 6.43%, N 29.77%.

Description and references

Potassium channel blocker. Prepn: A. Kirpal, Monatsh. Chem. 23, 244 (1902); R. Camps, Arch. Pharm. 240, 345 (1902) DOI; C. R. Hauser, G. A. Reynolds, J. Org. Chem. 15, 1224 (1950) DOI. Prolongs action potential in demyelinated nerve fibers: R. M. Sherratt et al., Nature 283, 570 (1980) DOI PubMed. HPLC determn in serum: A. van der Horst et al., J. Chromatogr. 574, 166 (1992) DOI PubMed. Clinical pharmacokinetics of sustained-release formulation in chronic, incomplete spinal cord injury: K. C. Hayes et al., Arch. Phys. Med. Rehabil. 85, 29 (2004) DOI PubMed. Neurophysiology and clinical efficacy in multiple sclerosis (MS): H. A. M. van Diemen et al., J. Neurol. Sci. 116, 220 (1993) DOI PubMed. Clinical evaluation: C. H. Polman et al., Arch. Neurol. 51, 1136 (1994) PubMed. Clinical trial of sustained-release formulation in MS: A. D. Goodman et al., Lancet 373, 732 (2009) DOI PubMed. Review of pharmacology and efficacy of aminopyridines in MS: C. T. Bever, Jr., Ann. Neurol. 36, S118-S121 (1994) DOI; of clinical experience in MS and spinal cord injury: K. C. Hayes, Expert Rev. Neurother. 7, 453-461 (2007) DOI PubMed.

Chemical structure

Properties

Crystals from CHCl3, mp 158-159°. Sol in water, alcohol; slightly sol in benzene, ether; very slightly sol in ligroin.

Therapeutic Category

In treatment of multiple sclerosis.

Keywords

Potassium Channel Blocker